Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study.

ABSTRACT:

Purpose

Persistent chemotherapy-related cognitive impairment (pCRCI) is commonly reported following cancer treatment and negatively affects quality of life; however, there is currently no pharmacological treatment indicated for pCRCI. This pilot study obtained preliminary data regarding the use of transdermal nicotine patches as a therapeutic strategy for women with pCRCI to (1) reduce subjective cognitive complaints and (2) enhance objective cognitive performance in breast, colon, lymphoma, or ovarian cancer survivors with pCRCI.

Methods

Participants were randomized to either placebo (n = 11) or transdermal nicotine (n = 11) for 6 weeks, followed by 2 weeks of treatment withdrawal for a total of 8 weeks. Participants were assessed using both subjective and objective measure

SUBMITTER: Vega JN 

PROVIDER: S-EPMC6993088 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature